Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer 8, 95 (2022).
Zerdan, M. B. et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers 14, 1253 (2022).
Li, X. et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat. 161, 279–287 (2017).
Hsu, J. Y., Chang, C. J. & Cheng, J. S. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci. Rep. 12, 729 (2022).
Obidiro, O., Battogtokh, G. & Akala, E.O. Triple negative breast cancer treatment options and limitations: future outlook, Pharmaceutics 15, 1796 (2023).
Fan, Y. & He, S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag. Res. 14, 1–17 (2022).
So, J. Y., Ohm, J., Lipkowitz, S. & Yang, L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. Pharm. Ther. 237, 108253 (2022).
Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554–577 (2024).
de Moraes, F. C. A., Souza, M. E. C., Sano, V. K. T., Moraes, R. A. & Melo, A. C. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Clin. Transl. Oncol. 27, 974–987 (2024).
Leon-Ferre, R.A. & International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA 331, 1135–1144 (2024).
Gao, G., Wang, Z., Qu, X. & Zhang, Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer 20, 179 (2020).
Luo, C. et al. Progress and prospect of immunotherapy for triple-negative breast cancer. Front. Oncol. 12, 919072 (2022).
Zhu, Y., Zhu, X., Tang, C., Guan, X. & Zhang, W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim. Biophys. Acta Rev. Cancer 1876, 188593 (2021).
Shewale, H. & Kanugo, A. Recent advances in immunotherapy and targeted therapy of triple negative breast cancer. Curr. Pharm. Biotechnol. 26, 365–391 (2024).
Liu, Y. et al. Advances in immunotherapy for triple-negative breast cancer. Mol. Cancer 22, 145 (2023).
Tarantino, P., Gandini, S., Trapani, D., Criscitiello, C. & Curigliano, G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Oncol. Hematol. 159, 103223 (2021).
Huo, X. et al. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Oncol. Hematol. 168, 103530 (2021).
Howard, F. M., Pearson, A. T. & Nanda, R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res. Treat. 195, 1–15 (2022).
Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090–1100 (2020).
Schmid, P., Dent, R. & O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, e108 (2020).
Chen, W. et al. CpG-based nanovaccines for cancer immunotherapy. Int. J. Nanomed. 16, 5281–5299 (2021).
Rolfo, C., Giovannetti, E., Martinez, P., McCue, S. & Naing, A. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. NPJ Precis. Oncol. 7, 26 (2023).
Hsu, M. Y. et al. Enhanced paclitaxel efficacy to suppress triple-negative breast cancer progression using metronomic chemotherapy with a controlled release system of electrospun poly-d-l-lactide-co-glycolide (PLGA) nanofibers. Cancers 13, 3350 (2021).
Hu, Q. et al. A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. SpringerPlus 3, 293 (2014).
Alfatama, M., Shahzad, Y. & Choukaife, H. Recent advances of electrospray technique for multiparticulate preparation: drug delivery applications. Adv. Colloid Interface Sci. 325, 103098 (2024).
Vigata, M., Meinert, C., Hutmacher, D. W. & Bock, N. Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques. Pharmaceutics 12, 1188 (2020).
Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91–113 (2022).
Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560–564 (2019).
Zhu, L. et al. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. J. Immunother. Cancer 7, 265 (2019).
Hutchinson, K. E. et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin. Cancer Res. 26, 657–668 (2020).
Cazzaniga, M.E. et al. Metronomic chemotherapy. Cancers 13, 2236 (2021).
Muraro, E. et al. Metronomic chemotherapy: anti-tumor pathways and combination with immune checkpoint inhibitors. Cancers 15 (2023).
Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S. & Naik, R. Combination strategies to augment immune check point inhibitors efficacy – implications for translational research. Front. Oncol. 11, 559161 (2021).
Tabata, Y. & Ikada, Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9, 356–62 (1988).
Sarmadi, M. et al. Modeling, design, and machine learning-based framework for optimal injectability of microparticle-based drug formulations. Sci. Adv. 6, eabb6594 (2020).
Su, C. et al. Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas. JCI Insight. 9, e178767 (2024).
Dongye, Z. et al. Icaritin and intratumoral injection of CpG treatment synergistically promote T cell infiltration and antitumor immune response in mice. Int. Immunopharmacol. 111, 109093 (2022).
Liu, J. et al. Programmable delivery of immune adjuvant to tumor-infiltrating dendritic cells for cancer immunotherapy. Nano Lett. 20, 4882–4889 (2020).
Kadiyala, P. et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13, 1365–1384 (2019).
Shirota, Y., Shirota, H. & Klinman, D. M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 188, 1592–9 (2012).
Ali, H. R. et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25, 1536–43 (2014).
Patras, L., Shaashua, L., Matei, I. & Lyden, D. Immune determinants of the pre-metastatic niche. Cancer Cell 41, 546–572 (2023).
Wang, Y. et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct. Target Ther. 9, 236 (2024).
Keklikoglou, I. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat. Cell Biol. 21, 190–202 (2019).
Monteran, L. et al. Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. Nat. Commun. 13, 5797 (2022).
Karagiannis, G. S., Condeelis, J. S. & Oktay, M. H. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin. Exp. Metastasis 35, 269–284 (2018).
Nishikawa, M. et al. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials 32, 488–94 (2011).
Hsu, M. Y. et al. Preparation and in vitro/in vivo evaluation of doxorubicin-loaded poly[lactic-co-glycol acid] microspheres using electrospray method for sustained drug delivery and potential intratumoral injection. Colloids Surf. B Biointerfaces 190, 110937 (2020).